Oki Hodaka, Hayashida Yoshiko, Oki Haruka, Kakeda Shingo, Aoki Takatoshi, Taguchi Masashi, Harada Masaru, Korogi Yukunori
Department of Radiology, University of Occupational and Environmental Health, Yahatanishi-ku, Kitakyushu, Fukuoka, Japan.
J Magn Reson Imaging. 2015 Jan;41(1):125-31. doi: 10.1002/jmri.24508. Epub 2013 Nov 22.
To compare the MR findings including diffusion-weighted imaging (DWI) between symptomatic and asymptomatic patients with autoimmune pancreatitis (AIP) and to determine whether DWI can be used as an objective biomarker for symptomatic AIP, which is considered an indication for steroid therapy.
This retrospective study was approved by our institutional review board. MRI scans from 37 patients with AIP (symptomatic, n = 19; asymptomatic, n = 18) were retrospectively evaluated. The imaging studies were performed on a 1.5 Tesla scanner and assessed for parenchymal enlargement, narrowing of the main pancreatic duct, hypointensity on fat-suppressed T1-weighted images (FS-T1WI), a capsule-like rim, extrapancreatic lesions, and hyperintensity on DWI. The findings were compared by univariate and multivariate logistic regression analysis. Apparent diffusion coefficient (ADC) values were also calculated.
Multivariate analysis showed that hyperintensity on DWI were most significantly associated with the symptoms of AIP (odds ratio = 28.2; P = 0.003). Interobserver agreement for DWI was also high. The ADC values were significantly lower in symptomatic than in asymptomatic patients (0.94 ± 0.17 versus 1.16 ± 0.16 × 10(-3) mm(2)/s, P < 0.001). Receiver operating characteristic curve analysis of the ADC values to differentiate between symptomatic and asymptomatic patients showed that sensitivity was 68.4%, specificity 83.3%, and AUC 0.74.
Signal intensity on DWI and ADC value were well correlated with the active symptoms of AIP patients. DWI may be useful as an objective biomarker for determining the indication for steroid therapy.
比较自身免疫性胰腺炎(AIP)有症状患者和无症状患者的磁共振成像(MRI)表现,包括扩散加权成像(DWI),并确定DWI是否可作为有症状AIP的客观生物标志物,有症状AIP被视为类固醇治疗的指征。
本回顾性研究经机构审查委员会批准。对37例AIP患者(有症状者19例,无症状者18例)的MRI扫描进行回顾性评估。成像研究在1.5特斯拉扫描仪上进行,评估胰腺实质增大、主胰管狭窄、脂肪抑制T1加权像(FS-T1WI)上的低信号、包膜样边缘、胰腺外病变以及DWI上的高信号。通过单因素和多因素逻辑回归分析比较研究结果。还计算了表观扩散系数(ADC)值。
多因素分析显示,DWI上的高信号与AIP的症状最显著相关(比值比=28.2;P=0.003)。DWI的观察者间一致性也很高。有症状患者ADC值显著低于无症状患者(0.94±0.17对1.16±0.16×10⁻³mm²/s,P<0.001)。ADC值用于区分有症状和无症状患者的受试者操作特征曲线分析显示,敏感性为68.4%,特异性为83.3%,曲线下面积(AUC)为0.74。
DWI上的信号强度和ADC值与AIP患者的活动症状密切相关。DWI可能作为确定类固醇治疗指征的客观生物标志物。